Article Figures & Data
Figures
- Fig 1.
A, Postcontrast T1-weighted MR image shows a biopsy site from a nonenhancing WHO grade II glioma. CBV (B) and PS maps (C) with regions of interest corresponding to the biopsy site show low CBV and PS. Hematoxylin-eosin (original magnification, ×20) (D), CD34 (E), and VEGFR-2 (F) stains show moderate cellularity (score 2), low MVD (score 1; 55 vessels/original magnification, ×20), MVCP (score 0), and negative VEGFR-2 immunoreactivity of the endothelial cells.
- Fig 2.
Box-and-whisker chart shows CBV and PS comparison of low- and high-grade glioma specimens.
- Fig 3.
A, Postcontrast T1-weighted MR image shows a biopsy site from a WHO grade IV glioma. CBV (B) and PS (C) maps with regions of interest corresponding to the biopsy site show very high CBV and PS. Hematoxylin-eosin, original magnification ×20 (D), CD34 (E), and VEGFR-2 (F) stains show high cellularity (score 3), high MVD (score 3, 263 vessels/original magnification ×20), MVCP (score 2), and VEGFR-2 staining of the endothelial cells in the vessel lumen.
- Fig 4.
Box-and-whisker chart shows CBV and PS comparison of VEGFR-2–positive and –negative glioma specimens.
Tables
Histopathology Parameter PCT Parameter Correlation Coefficient P Valuea MVCP CBV 0.414 .095 CBF 0.477 .051 MTT −0.170 .392 PS 0.647 .001b MVD CBV 0.649 .002b CBF 0.527 .016b MTT −0.233 .227 PS 0.332 .073 Tumor cellularity CBV 0.482 .012b CBF 0.498 .014b MTT −0.110 .572 PS 0.409 .016b WHO grade CBV 0.623 .008b CBF 0.672 .002b MTT −0.291 .142 PS 0.659 <.001b a P value from clustering methods, which take into account multiple samples from the same patient.
b Statistically significant.
PCT Parameter VEGFR-2–Positive (mean ± SE) VEGFR-2–Negative (mean ± SE) PValue CBV (mL/100 g) 2.39 ± 0.94 1.39 ± 0.22 .316 CBF (mL/100 g/min) 70.69 ± 34.99 26.17 ± 5.25 .197 MTT (second) 3.86 ± 0.75 5.19 ± 1.11 .402 PS (mL/100 g/min) 2.90 ± 1.22 0.56 ± 0.12 .071
In this issue
Jump to section
Related Articles
Cited By...
- Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis
- Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging
- Correlation of Tumor Immunohistochemistry with Dynamic Contrast-Enhanced and DSC-MRI Parameters in Patients with Gliomas
- Differentiating Hemangioblastomas from Brain Metastases Using Diffusion-Weighted Imaging and Dynamic Susceptibility Contrast-Enhanced Perfusion-Weighted MR Imaging
- T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status
- Glioma Angiogenesis and Perfusion Imaging: Understanding the Relationship between Tumor Blood Volume and Leakiness with Increasing Glioma Grade
- Histogram Analysis of Intravoxel Incoherent Motion for Differentiating Recurrent Tumor from Treatment Effect in Patients with Glioblastoma: Initial Clinical Experience
- Intratumoral Modeling of Gefitinib Pharmacokinetics and Pharmacodynamics in an Orthotopic Mouse Model of Glioblastoma
- Correlation of Perfusion Parameters with Genes Related to Angiogenesis Regulation in Glioblastoma: A Feasibility Study
- Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study
- Perfusion CT Imaging of Brain Tumors: An Overview
- Permeability Estimates in Histopathology-Proved Treatment-Induced Necrosis Using Perfusion CT: Can These Add to Other Perfusion Parameters in Differentiating from Recurrent/Progressive Tumors?